vs
Genius Sports Ltd（GENI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Genius Sports Ltd的1.2倍（$622.0M vs $510.9M），Royalty Pharma plc净利率更高（34.4% vs -12.3%，领先46.8%），过去两年Genius Sports Ltd的营收复合增速更高（129.2% vs 4.6%）
Genius Sports是一家体育数据与科技企业，为体育联盟、博彩机构及媒体公司提供数据管理、视频流媒体和赛事诚信服务，致力于帮助合作伙伴优化运营效率、丰富用户体验，保障体育赛事的公平透明与商业价值落地。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
GENI vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.2倍
$510.9M
净利率更高
RPRX
高出46.8%
-12.3%
两年增速更快
GENI
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $510.9M | $622.0M |
| 净利润 | $-63.0M | $214.2M |
| 毛利率 | 25.2% | — |
| 营业利润率 | -11.5% | 62.4% |
| 净利率 | -12.3% | 34.4% |
| 营收同比 | — | 4.8% |
| 净利润同比 | — | 2.9% |
| 每股收益（稀释后） | — | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GENIRPRX
| Q4 25 | $510.9M | $622.0M | ||
| Q3 25 | $335.4M | $609.3M | ||
| Q2 25 | $215.2M | $578.7M | ||
| Q1 25 | $119.7M | $568.2M | ||
| Q4 24 | $413.0M | $593.6M | ||
| Q3 24 | $285.8M | $564.7M | ||
| Q2 24 | $184.1M | $537.3M | ||
| Q1 24 | $97.2M | $568.0M |
净利润GENIRPRX
| Q4 25 | $-63.0M | $214.2M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | $-47.3M | $30.2M | ||
| Q1 25 | $-25.5M | $238.3M | ||
| Q4 24 | $-85.5M | $208.2M | ||
| Q3 24 | $-47.1M | $544.0M | ||
| Q2 24 | $-35.5M | $102.0M | ||
| Q1 24 | $-25.2M | $4.8M |
毛利率GENIRPRX
| Q4 25 | 25.2% | — | ||
| Q3 25 | 24.2% | — | ||
| Q2 25 | 19.1% | — | ||
| Q1 25 | 10.7% | — | ||
| Q4 24 | 16.7% | — | ||
| Q3 24 | 20.5% | — | ||
| Q2 24 | 18.6% | — | ||
| Q1 24 | 9.8% | — |
营业利润率GENIRPRX
| Q4 25 | -11.5% | 62.4% | ||
| Q3 25 | -15.3% | 70.1% | ||
| Q2 25 | -21.0% | 36.3% | ||
| Q1 25 | -20.3% | 94.0% | ||
| Q4 24 | -18.0% | 60.9% | ||
| Q3 24 | -13.9% | — | ||
| Q2 24 | -16.8% | 50.2% | ||
| Q1 24 | -23.7% | -13.0% |
净利率GENIRPRX
| Q4 25 | -12.3% | 34.4% | ||
| Q3 25 | — | 47.3% | ||
| Q2 25 | -22.0% | 5.2% | ||
| Q1 25 | -21.3% | 41.9% | ||
| Q4 24 | -20.7% | 35.1% | ||
| Q3 24 | -16.5% | 96.3% | ||
| Q2 24 | -19.3% | 19.0% | ||
| Q1 24 | -25.9% | 0.8% |
每股收益（稀释后）GENIRPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | — | $0.67 | ||
| Q2 25 | — | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | — | $1.21 | ||
| Q2 24 | — | $0.23 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $280.6M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $724.5M | $9.7B |
| 总资产 | $1.1B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资GENIRPRX
| Q4 25 | $280.6M | $618.7M | ||
| Q3 25 | $110.2M | $938.9M | ||
| Q2 25 | $110.2M | $631.9M | ||
| Q1 25 | $110.2M | $1.1B | ||
| Q4 24 | $100.3M | $929.0M | ||
| Q3 24 | $100.3M | $950.1M | ||
| Q2 24 | $100.3M | $1.8B | ||
| Q1 24 | $100.3M | $843.0M |
总债务GENIRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益GENIRPRX
| Q4 25 | $724.5M | $9.7B | ||
| Q3 25 | $572.4M | $9.6B | ||
| Q2 25 | $572.4M | $9.5B | ||
| Q1 25 | $572.4M | $9.8B | ||
| Q4 24 | $573.0M | $10.3B | ||
| Q3 24 | $573.0M | $10.3B | ||
| Q2 24 | $573.0M | $9.8B | ||
| Q1 24 | $573.0M | $9.9B |
总资产GENIRPRX
| Q4 25 | $1.1B | $19.6B | ||
| Q3 25 | $792.3M | $19.3B | ||
| Q2 25 | $792.3M | $18.3B | ||
| Q1 25 | $792.3M | $17.6B | ||
| Q4 24 | $775.7M | $18.2B | ||
| Q3 24 | $775.7M | $18.0B | ||
| Q2 24 | $775.7M | $17.7B | ||
| Q1 24 | $775.7M | $16.1B |
负债/权益比GENIRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $81.9M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $69.6M | — |
| 自由现金流率自由现金流/营收 | 13.6% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $33.5M | — |
8季度趋势，按日历期对齐
经营现金流GENIRPRX
| Q4 25 | $81.9M | $827.1M | ||
| Q3 25 | $-4.8M | $702.6M | ||
| Q2 25 | $-1.2M | $364.0M | ||
| Q1 25 | $-14.6M | $596.1M | ||
| Q4 24 | $14.9M | $742.5M | ||
| Q3 24 | $-9.2M | $703.6M | ||
| Q2 24 | — | $658.2M | ||
| Q1 24 | — | $664.6M |
自由现金流GENIRPRX
| Q4 25 | $69.6M | — | ||
| Q3 25 | $-14.2M | — | ||
| Q2 25 | $-5.8M | — | ||
| Q1 25 | $-16.0M | — | ||
| Q4 24 | $11.3M | — | ||
| Q3 24 | $-11.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率GENIRPRX
| Q4 25 | 13.6% | — | ||
| Q3 25 | -4.2% | — | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | -13.4% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | -4.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度GENIRPRX
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率GENIRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GENI
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
